Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 64 of 64 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/31/12
End: 09/30/12
Due: 09/30/13
Phase: N/A
Priority: Normal
Start: 11/30/10
End: 03/31/13
Due: 03/31/14
Phase: N/A
Priority: Normal
Start: 02/01/19
End: 11/22/19
Due: 11/22/20
Phase: N/A
Priority: Normal
Start: 02/28/10
End: 12/31/11
Due: 12/31/12
Phase: N/A
Priority: Normal
Start: 08/31/11
End: 11/30/13
Due: 11/30/14
Phase: N/A
Priority: Normal
Start: 10/31/14
End: 07/31/15
Due: 07/31/16
Phase: N/A
Priority: Normal
Start: 11/09/15
End: 10/12/17
Due: 10/12/18
Phase: N/A
Priority: Normal
Start: 05/31/14
End: 10/31/14
Due: 10/31/15
Phase: N/A
Priority: Normal
Start: 05/31/12
End: 06/30/13
Due: 06/30/14
Phase: N/A
Priority: Normal
Start: 10/31/10
End: 05/31/13
Due: 05/31/14
Phase: N/A
Priority: Normal
Start: 05/31/14
End: 12/31/16
Due: 12/31/17
Phase: N/A
Priority: Normal
Start: 12/31/07
End: 10/31/12
Due: 10/31/13
Phase: N/A
Priority: Normal
Start: 05/31/09
End: 12/31/09
Due: 12/31/10
Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer
Phase: N/A
Priority: Normal
Start: 01/31/15
End: 06/30/17
Due: 06/30/18